{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:53:27Z","timestamp":1790744007651,"version":"4.1.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.lungcan.2016.02.015","type":"journal-article","created":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T22:31:50Z","timestamp":1456871510000},"page":"35-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient"],"prefix":"10.1016","volume":"95","author":[{"given":"Janine","family":"Doesch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin S","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim H.","family":"Ficker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang M.","family":"Brueckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lungcan.2016.02.015_bib0005","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1586\/era.13.30","article-title":"Dermatologic adverse events associated with afatinib: an oral ErbB family blocker","volume":"13","author":"Lacouture","year":"2013","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"2","key":"10.1016\/j.lungcan.2016.02.015_bib0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-013-0170-8","article-title":"Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer","volume":"74","author":"Keating","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.lungcan.2016.02.015_bib0015","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Harr","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.lungcan.2016.02.015_bib0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2016.02.015_bib0025","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1159\/000342671","article-title":"Toxic epidermal necrolysis related to Cisplatin and pemetrexed for metastatic non-small cell lung cancer","volume":"35","author":"Scheinpflug","year":"2012","journal-title":"Onkologie"},{"issue":"2","key":"10.1016\/j.lungcan.2016.02.015_bib0030","doi-asserted-by":"crossref","first-page":"94","DOI":"10.5732\/cjc.014.10151","article-title":"Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer","volume":"34","author":"Huang","year":"2014","journal-title":"Chin. J. Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2016.02.015_bib0035","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/j.1365-4632.2011.05356.x","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis overlap in a patient receiving cetuximab and radiotherapy for head and neck cancer","volume":"51","author":"Urosevic-Maiwald","year":"2012","journal-title":"Int. J. Dermatol."},{"issue":"4","key":"10.1016\/j.lungcan.2016.02.015_bib0040","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.amjoto.2009.02.021","article-title":"Toxic epidermal necrolysis caused by cetuximab plus minocycline in head and neck cancer","volume":"31","author":"Lee","year":"2016","journal-title":"Am. J. Otolaryngol."},{"issue":"16","key":"10.1016\/j.lungcan.2016.02.015_bib0045","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1200\/JCO.2007.15.7883","article-title":"Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer","volume":"26","author":"Lin","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2016.02.015_bib0050","doi-asserted-by":"crossref","first-page":"142","DOI":"10.5582\/ddt.2015.01019","article-title":"Crizotinib-associated erythema multiforme in a lung cancer patient","volume":"9","author":"Sawamura","year":"2015","journal-title":"Drug Discov. Ther."},{"issue":"3","key":"10.1016\/j.lungcan.2016.02.015_bib0055","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s40629-015-0052-6","volume":"24","author":"Brockow","year":"2015","journal-title":"Allergo J. Int."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216302318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216302318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T14:25:14Z","timestamp":1536935114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500216302318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":11,"alternative-id":["S0169500216302318"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.02.015","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}